Truist analysts wrote that Medtronic, Boston Scientific and Edwards Lifesciences could benefit from rising cardiology volumes, while Intuitive Surgical may benefit from improved capital spending.
Truist analysts wrote that Medtronic, Boston Scientific and Edwards Lifesciences could benefit from rising cardiology volumes, while Intuitive Surgical may benefit from improved capital spending.